Journal
JOURNAL OF IMMUNOLOGY
Volume 186, Issue 12, Pages 6798-6806Publisher
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.1004222
Keywords
-
Categories
Funding
- Canadian Institutes of Health Research [MOP-86468]
- National Institutes of Health [1R21A1089963]
- Natural Sciences and Engineering Research Council of Canada
Ask authors/readers for more resources
Adenosine has been established as an important regulator of immune activation. It signals through P1 adenosine receptors to suppress activation of T cells and professional APCs. Adenosine deaminase (ADA) counters this effect by catabolizing adenosine. This regulatory mechanism has not been tested in a disease model in vivo. Questions also remain as to which cell types are most sensitive to this regulation and whether its dysregulation contributes to any autoimmune conditions. We approached this issue using the NOD model. We report that ADA is upregulated in NOD dendritic cells, which results in their exuberant and spontaneous activation. This, in turn, triggers autoimmune T cell activation. NOD DCs deficient in ADA expression have a greatly reduced capacity to trigger type I diabetes. We also provide evidence that although many cell types, particularly T cells, have been implicated as the suppression targets by adenosine in an in vitro setting, DCs also seem to be affected by this regulatory mechanism. Therefore, this report illustrates a role of ADA in autoimmunity and suggests a potential target for therapeutic intervention. The Journal of Immunology, 2011, 186: 6798-6806.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available